Our

Pipeline

Our Pipeline Includes Potential First- Or
Best-In-Class Molecules

Cullinan Therapeutics has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases.
pipeline-best-in-class
Image of Circles
CLN-619
Anti-MICA/B antibody
Phase 1
 
Pan-cancer
Status:
Initial combo data and monotherapy update in 2Q24; Disease specific expansion data in 1H25
CLN-978
CD19xCD3 T-cell engager
IND-Enabling
 
Systemic lupus erythematosus (SLE)
Status:
IND submission expected in Q3 2024

Zipalertinib (CLN-081/TAS6417)

EGFRex20ins inhibitor
Phase 2
 
NSCLC with exon 20 insertion mutations 2+ line
NSCLC with exon 20 insertion mutations frontline
Status:
Pivotal Phase 2b 2L+ study enrolled  by YE24; Phase 3 1L study actively  enrolling
CLN-049
FLT3xCD3 T-cell engager
Phase 1
 
R/R AML, MDS
Status:
Clinical update from ongoing Phase 1 study in 2H24
CLN-418
B7H4x41BB bispecific immune activator
Phase 1
 
Multiple solid tumors
Status:
Clinical update from ongoing Phase 1 study in 2H24
CLN-617
Collagen-binding IL-12-IL2 fusion protein
Phase 1
 
Pan-cancer
Status:
Phase 1 study ongoing

Early Programs

Powered by our novel research model, we push conventional boundaries from candidate selection to differentiated therapeutics, applying rigorous go/no-go criteria at each stage of development to fast-track only the most promising assets to the clinic and, ultimately, commercialization. Early programs we’re currently exploring include:

T-cell Receptor (TCR) – TCR-based construct that targets MHC molecules presenting a peptide derived from a nucleolar protein that is highly expressed in many cancers.

HPK1 Targeting – A potential first-in-class protein degrader that acts as a negative regulator of T cells and TCR signaling.

 
 

Our Differentiated Assets

Our portfolio encompasses a wide range of modalities, each with the potential to be best- and/or first-in-class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.
 

Harnessing Science for Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.